Literature DB >> 21269567

Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients.

Yangqiu Li1, Suxia Geng, Xin Du, Shaohua Chen, Lijian Yang, Xiuli Wu, Bo Li, Christian A Schmidt, Grzegorz K Przybylski.   

Abstract

T-cell immunodeficiency is a common feature in cancer patients, which may relate to initiation and development of tumor. In expanding our previous observations in this area, we studied the repertoire of T-cell receptor beta variable region (TRBV) and T-cell proliferative history in CD4+ and CD8+ T cells from chronic myeloid leukemia (CML) patients. The expression and clonality analysis were performed by reverse transcription-polymerase chain reaction (RT-PCR) and GeneScan technique in peripheral blood mononuclear cells (PBMCs), CD4+ and CD8+ subsets of T cells. Nineteen CML cases in chronic phase were selected for this study and 17 healthy individuals served as controls. Marked restriction of TRBV repertoire was observed in both CD4+ and CD8+ T cells from CML. In most CML samples, clonally expanded T cells were identified in CD4+ and CD8+ T cells, predominantly in TRBV19 and TRBV21 (5/19) subfamilies. In conclusion, the restricted expression of TRBV subfamilies indicates the T-cell immunodeficiency in CML patients; however, clonally expanded T cells suggest a specific immune response to leukemia associated antigens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269567     DOI: 10.1179/102453311X12902908411634

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  9 in total

1.  Upregulated TCRζ enhances interleukin-2 production in T-cells from patients with CML.

Authors:  Xianfeng Zha; Shaohua Chen; Lijian Yang; Li Shi; Bo Li; Xiuli Wu; Yuhong Lu; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2012-10-11       Impact factor: 3.311

2.  Arsenic induced complete remission in a refractory T-ALL patient with a distinct T-cell clonal evolution without molecular complete remission: A case report.

Authors:  Suijing Wu; Ling Xu; Xin Huang; Suxia Geng; Yan Xu; Shaohua Chen; Lijian Yang; Xiuli Wu; Janyu Weng; Xin DU; Yangqiu Li
Journal:  Oncol Lett       Date:  2016-05-05       Impact factor: 2.967

Review 3.  Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.

Authors:  Ya-Ching Hsieh; Kristina Kirschner; Mhairi Copland
Journal:  Leukemia       Date:  2021-04-08       Impact factor: 12.883

4.  Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia.

Authors:  Zhenyi Jin; Qiang Luo; Shuai Lu; Xinyu Wang; Zifan He; Jing Lai; Shaohua Chen; Lijian Yang; Xiuli Wu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2016-11-18       Impact factor: 17.388

Review 5.  Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.

Authors:  Amy Hughes; Agnes S M Yong
Journal:  Front Immunol       Date:  2017-04-24       Impact factor: 7.561

6.  Age-Related Immune Profile of the T Cell Receptor Repertoire, Thymic Recent Output Function, and miRNAs.

Authors:  Yan Xu; Ling Xu; Cunte Chen; Yikai Zhang; Chengwu Zeng; Zhenyi Jin; Shaohua Chen; Bo Li; Xianfeng Zha; Zhinan Yin; Yangqiu Li
Journal:  Biomed Res Int       Date:  2020-12-02       Impact factor: 3.411

7.  New insights into antigen specific immunotherapy for chronic myeloid leukemia.

Authors:  Yangqiu Li; Chen Lin; Christian A Schmidt
Journal:  Cancer Cell Int       Date:  2012-12-15       Impact factor: 5.722

8.  Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia.

Authors:  Xianfeng Zha; Xiaojuan Yan; Qi Shen; Yuping Zhang; Xiuli Wu; Shaohua Chen; Bo Li; Lijian Yang; Suxia Geng; Jianyu Weng; Xin Du; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2012-12-10       Impact factor: 17.388

Review 9.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Authors:  Li Shi; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2013-09-30       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.